Adwait Oka

Company: Novartis AG

Job title: Principal Scientist

Seminars:

A First-in-Class Anti-CD19, Anti-CD3, Anti-CD2 Trispecific Antibody (PIT565) for the Treatment of B Cell Malignancies 11:00 am

PIT565 is a first-in-class, CD19xCD3xCD2, IgG-like, trispecific antibody that targets CD19+ cells and at the same time engages CD3 and CD2 (a costimulatory receptor) on T cells, which leads to redirected T-cell cytotoxicity toward CD19-positive malignant B cell Preclinical data demonstrate more robust anti-tumor response and overall T cell effector functions compared with the bispecific…Read more

day: Conference Day 2